Disseminated Tuberculosis With an Atypical Cutaneous Manifestation in a Hematopoietic Cell Transplant Patient in the Early Posttransplant Period: Case Report and Review of the Literature. (29th November 2022)

• Record Type: Journal Article
• Authors: Czech, Mary M; Dioverti, Maria Veronica; Karaba, Andrew H; Jain, Tania; Talluru, Sai M; Sunshine, Joel C; Kang, Jun; Parrish, Nikki; Kates, Olivia S
• Is Part Of: Open forum infectious diseases. Volume 9:Number 12(2022)
• Publication Date: 2022-11-29
• Subjects: cutaneous tuberculosis -- disseminated tuberculosis -- hematopoietic cell transplant -- tuberculosis pustules -- tuberculosis reactivation; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac643
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: We describe an unusual case of posttransplant tuberculosis reactivation in a man who underwent allogeneic hematopoietic cell transplant. Concomitant with disseminated adenovirus infection, reactivation of tuberculosis manifested as disseminated, nonfollicular pustules on day +49. Skin biopsy was obtained on day +50. Initial histopathologic evaluation did not suggest mycobacterial infection, but tissue stain showed acid-fast organisms, which were subsequently identified as Mycobacterium tuberculosis . Shortly after the cutaneous presentation of tuberculosis, the patient died on day +52. Our case is among a paucity of reports describing tuberculosis reactivation in hematopoietic cell transplant patients in the early posttransplant period. It highlights the difficulty of diagnosing contemporaneous systemic infections, and it presents a rare and atypical cutaneous manifestation of tuberculosis in a hematopoietic cell transplant patient. Our case and review of the literature emphasize the need for further research to elucidate risk factors associated with early posttransplant reactivation of tuberculosis, and the importance of remaining vigilant for active tuberculosis in hematopoietic cell transplant patients with epidemiologic risk factors.